The Clinical Trials Office (CTO) Shared Resource has as its mission the support of clinical trials by Yale Cancer Center members. This Shared Resource, coupled with the staff of the Protocol Specific Research Support (PSRS) Shared Resource [also referred to as the Clinical Trials Institutional Research Core (CTIRC)] and the Clinical Protocol Review and Monitoring System (CPRMS) Shared Resource, provides the nursing, data management, protocol development expertise, regulatory guidance and patient access needed to successfully conduct Phase I, II and III studies. The long term goal of this Shared Resource is to make it possible for Yale investigators to conduct innovative trials rapidly, in accord with good clinical practice guidelines, with accurate data collection and data available on line in a user friendly data base. This data base has been creative in collaboration with the Center for Medical Informatics and has been adopted by the Medical School as the standard for clinical trials in all area. In the past two years a new clinical trials programs has been added, the Yale Oncology Network (YON), under the direction of the Associate Director for Clinical Trials. YON represents a consortium of hospitals and practices in the State of Connecticut whose purpose is to conduct state of the art clinical trials in the community setting. The CTO plays a critical role in the functionality of the YON by providing administrative and technical support. The focus of this Shared Resource will be Phase I and II studies, especially those which evaluate critical scientific hypotheses, evaluate novel therapies and test promising new agents up through and including studies of proof of concept. The program will continue to evaluate traditional cytotoxics, biologicals as well as new classes of agents.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016359-24
Application #
6101785
Study Section
Project Start
1998-09-23
Project End
1999-06-30
Budget Start
Budget End
Support Year
24
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40
Kim, Tae Kon; Herbst, Roy S; Chen, Lieping (2018) Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 39:624-631
Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025
Wang, Shi-Yi; Long, Jessica B; Killelea, Brigid K et al. (2018) Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Res Treat 172:453-461
Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331
De Feyter, Henk M; Behar, Kevin L; Corbin, Zachary A et al. (2018) Deuterium metabolic imaging (DMI) for MRI-based 3D mapping of metabolism in vivo. Sci Adv 4:eaat7314
Ventura, Alessandra; Vassall, Aaron; Robinson, Eve et al. (2018) Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anticancer Immunity. Cancer Res 78:4045-4058
Xiao, Qian; Wu, Jibo; Wang, Wei-Jia et al. (2018) DKK2 imparts tumor immunity evasion through ?-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med 24:262-270

Showing the most recent 10 out of 675 publications